A temporary approach to neuromodulation
Targeting the nerve involved in pain
Peripheral nerve stimulation sends mild electrical pulses to a nerve outside the brain and spinal cord. SPRINT PNS uses a thin MicroLead placed near the targeted nerve and a small wearable pulse generator.
The treatment is designed for temporary use. The MicroLead is removed after the treatment period rather than remaining as a permanent implant.
A defined treatment period
The system is used for up to 60 days. Some patients notice relief early, while others find that relief develops over several weeks. Results vary.
How SPRINT PNS may provide relief
Rebalancing the signals your brain receives
The manufacturer describes a three-stage concept before, during, and following temporary stimulation.
Three primary components
A small system you control
SPRINT PNS combines a wearable stimulator, wireless remote, and targeted MicroLead.
During the treatment period
Living with the system
Your care team will explain activity, site-care, showering, and driving instructions for the treatment period.
Patient education
Resources
The approved toolkit includes additional videos and imagery once accessed through the SPRinstitute login.
Important safety information
The SPRINT Peripheral Nerve Stimulation (PNS) System is indicated for pain management in adults who have severe intractable chronic pain of peripheral nerve origin, as the sole mitigating agent, or as an adjunct to other modes of therapy used in a multidisciplinary approach. It is intended to be implanted for up to 60 days and provide sustained pain relief for up to three months after treatment ends.
The SPRINT PNS System is not intended to be placed in the region innervated by cranial and facial nerves. Physicians should use their best judgment when deciding when to use the system. The most common adverse events are skin irritation and erythema. Results may vary. Rx only.
Source and publication note
Sources: Karli Wandling and Krista Jenkins approved-materials emails; official SPR patient brochure, patient website, what-to-expect page, and 2026 indication/safety pages. The Digital Toolkit remains behind a quick-login portal. Replace the provisional public product image with the unbranded toolkit asset before publication if SPR requires it.
SPRINT and SPR are registered trademarks of SPR.
